| Purdue Pharma LP | Purdue Pharma | fraud | 2020 | DOJ_CIVIL | $8,344,000,000 |
| GlaxoSmithKline LLC | GlaxoSmithKline | off-label or unapproved promotion of medical products | 2012 | FDA | $3,000,000,000 |
| Pfizer Inc. | Pfizer | off-label or unapproved promotion of medical products | 2009 | FDA | $2,300,000,000 |
| Johnson & Johnson | Johnson & Johnson | off-label or unapproved promotion of medical products | 2013 | FDA | $2,200,000,000 |
| Mallinckrodt | Mallinckrodt | Controlled Substances Act violation | 2020 | MULTI-AG | $1,600,000,000 |
| Abbott Laboratories Inc. | AbbVie | off-label or unapproved promotion of medical products | 2012 | FDA | $1,500,000,000 |
| Eli Lilly and Company | Eli Lilly | off-label or unapproved promotion of medical products | 2009 | FDA | $1,415,000,000 |
| Cephalon, Inc. | Teva Pharmaceutical Industries | consumer protection violation | 2015 | FTC | $1,200,000,000 |
| Merck, Sharp & Dohme | Merck | off-label or unapproved promotion of medical products | 2011 | FDA | $950,000,000 |
| TAP Pharmaceutical Products Inc. | Takeda Pharmaceutical | False Claims Act and related | 2001 | DOJ_CIVIL | $875,000,000 |
| Pfizer Inc. | Pfizer | False Claims Act and related | 2016 | DOJ_CIVIL | $784,600,000 |
| Amgen Inc. | Amgen | off-label or unapproved promotion of medical products | 2012 | FDA | $762,000,000 |
| SB Pharmco Puerto Rico Inc. | GlaxoSmithKline | drug or medical equipment safety violation | 2010 | FDA | $750,000,000 |
| Serono, S.A. | Merck KGaA (EMD) | off-label or unapproved promotion of medical products | 2005 | FDA | $704,000,000 |
| Merck & Company | Merck | False Claims Act and related | 2008 | DOJ_CIVIL | $650,000,000 |
| Novartis Pharmaceuticals Corporation | Novartis | False Claims Act and related | 2020 | DOJ_CIVIL | (*) $642,000,000 |
| Amgen Inc. | Amgen | off-label or unapproved promotion of medical products | 2012 | MULTI-AG | (*) $612,000,000 |
| Allergan Inc. | AbbVie | off-label or unapproved promotion of medical products | 2010 | FDA | $600,000,000 |
| Abbott Laboratories and CG Nutritionals | Abbott Laboratories | False Claims Act and related | 2003 | DOJ_CIVIL | $600,000,000 |
| Indivior Solutions | Indivior Inc. | False Claims Act and related | 2020 | DOJ_CIVIL | $589,000,000 |
| Johnson & Johnson | Johnson & Johnson | off-label or unapproved promotion of medical products | 2013 | MULTI-AG | (*) $541,000,000 |
| AstraZeneca LP | AstraZeneca | off-label or unapproved promotion of medical products | 2010 | FDA | $520,000,000 |
| Bristol-Myers Squibb Company | Bristol-Myers Squibb | off-label or unapproved promotion of medical products | 2007 | DOJ_CIVIL | $515,000,000 |
| Ranbaxy USA Inc. | Sun Pharmaceuticals | drug or medical equipment safety violation | 2013 | FDA | $500,000,000 |
| Schering-Plough Corporation | Merck | drug or medical equipment safety violation | 2002 | DOJ_CIVIL | $500,000,000 |
| Wyeth Pharmaceuticals Inc. | Pfizer | off-label or unapproved promotion of medical products | 2013 | FDA | $490,900,000 |
| GlaxoSmithKline | GlaxoSmithKline | off-label or unapproved promotion of medical products | 2012 | MULTI-AG | (*) $477,792,391 |
| Mylan Inc. | Viatris | False Claims Act and related | 2017 | DOJ_CIVIL | $465,000,000 |
| Mylan Inc. | Viatris | False Claims Act and related | 2017 | MULTI-AG | (*) $465,000,000 |
| Purdue Frederick Company Inc. | Purdue Pharma | False Claims Act and related | 2007 | USAO | $461,900,000 |
| Schering-Plough Corporation | Merck | off-label or unapproved promotion of medical products | 2006 | USAO | $435,000,000 |
| Warner-Lambert | Pfizer | off-label or unapproved promotion of medical products | 2004 | FDA | $430,000,000 |
| Cephalon Inc | Teva Pharmaceutical Industries | off-label or unapproved promotion of medical products | 2008 | FDA | $425,000,000 |
| Novartis Pharmaceuticals Corporation | Novartis | off-label or unapproved promotion of medical products | 2010 | FDA | $422,500,000 |
| Janssen Pharmaceuticals, Inc. | Johnson & Johnson | off-label or unapproved promotion of medical products | 2013 | USAO | $410,000,000 |
| Novartis Pharmaceuticals | Novartis | kickbacks and bribery | 2015 | USAO | $390,000,000 |
| Wyeth Pharmaceuticals, Inc. | Pfizer | False Claims Act and related | 2016 | MULTI-AG | (*) $371,351,180 |
| Eli Lilly and Company | Eli Lilly | off-label or unapproved promotion of medical products | 2009 | MULTI-AG | (*) $361,828,456 |
| Actelion Pharmaceuticals US, Inc. | Johnson & Johnson | False Claims Act and related | 2018 | DOJ_CIVIL | $360,000,000 |
| AstraZeneca Pharmaceuticals LP | AstraZeneca | False Claims Act and related | 2003 | DOJ_CIVIL | $354,900,000 |
| Shire Pharmaceuticals LLC | Takeda Pharmaceutical | False Claims Act and related | 2017 | DOJ_CIVIL | $350,000,000 |
| Schering-Plough Corporation | Merck | kickbacks and bribery | 2004 | DOJ_CIVIL | $345,000,000 |
| Abbott Laboratories | AbbVie | off-label or unapproved promotion of medical products | 2012 | MULTI-AG | (*) $339,148,643 |
| Pfizer, Inc. | Pfizer | kickbacks and bribery | 2009 | MULTI-AG | (*) $331,485,170 |
| Bristol-Myers Squibb | Bristol-Myers Squibb | fraud | 2005 | USAO | $300,000,000 |
| Schering-Plough Corporation | Merck | kickbacks and bribery | 2004 | MULTI-AG | (*) $292,969,482 |
| Merck | Merck | False Claims Act and related | 2008 | MULTI-AG | (*) $290,000,000 |
| Teva Pharmaceutical Industries Ltd | Teva Pharmaceutical Industries | Foreign Corrupt Practices Act | 2016 | DOJ_CRIMINAL | $283,177,348 |
| Dey Inc. | Viatris | False Claims Act and related | 2010 | DOJ_CIVIL | $280,000,000 |
| Roxane Laboratories Inc. | Hikma Pharmaceuticals | False Claims Act and related | 2010 | DOJ_CIVIL | $280,000,000 |
| Celgene Corp. | Bristol-Myers Squibb | False Claims Act and related | 2017 | USAO | $280,000,000 |
| Purdue Pharma | Purdue Pharma | Controlled Substances Act violation | 2019 | OK-AG | $270,000,000 |
| Ranbaxy | Sun Pharmaceuticals | drug or medical equipment safety violation | 2013 | MULTI-AG | (*) $266,729,715 |
| Serono Inc. | Merck KGaA (EMD) | off-label or unapproved promotion of medical products | 2005 | MULTI-AG | (*) $262,000,000 |
| Wyeth Pharmaceuticals, Inc. | Pfizer | off-label or unapproved promotion of medical products | 2013 | MULTI-AG | (*) $257,400,000 |
| Teva Pharmaceutical Industries Limited | Teva Pharmaceutical Industries | Foreign Corrupt Practices Act | 2016 | SEC | $236,000,000 |
| Novartis Hellas S.A.C.I. et al. | Novartis | Foreign Corrupt Practices Act | 2020 | DOJ_CRIMINAL | $233,000,000 |
| Insys Therapeutics | Insys Therapeutics | False Claims Act and related | 2019 | DOJ_CIVIL | $225,000,000 |
| AstraZeneca Pharmaceuticals LP | AstraZeneca | off-label or unapproved promotion of medical products | 2010 | MULTI-AG | (*) $218,092,993 |
| United Therapeutics Corporation | United Therapeutics | False Claims Act and related | 2017 | DOJ_CIVIL | $210,000,000 |
| Elan Corporation PLC | Perrigo | off-label or unapproved promotion of medical products | 2010 | FDA | $203,000,000 |
| Merck Sharp & Dohme Corp. | Merck | off-label or unapproved promotion of medical products | 2012 | MULTI-AG | (*) $201,975,000 |
| Sandoz Inc. | Novartis | price-fixing or anti-competitive practices | 2020 | DOJ_ANTITRUST | $195,000,000 |
| Endo Health Solutions Inc. | Endo International | off-label or unapproved promotion of medical products | 2014 | FDA | $192,700,000 |
| Aventis Pharmaceuticals Inc. | Sanofi | False Claims Act and related | 2007 | DOJ_CIVIL | $190,000,000 |
| Warner-Lambert | Pfizer | off-label or unapproved promotion of medical products | 2004 | MULTI-AG | (*) $190,000,000 |
| Bristol-Myers Squibb | Bristol-Myers Squibb | False Claims Act and related | 2008 | MULTI-AG | (*) $187,000,000 |
| Janssen Pharmaceuticals, Inc. | Johnson & Johnson | off-label or unapproved promotion of medical products | 2012 | MULTI-AG | $181,000,000 |
| Novartis Corporation | Novartis | employment discrimination | 2010 | private lawsuit-federal | $175,000,000 |
| Endo Health Solution | Endo International | off-label or unapproved promotion of medical products | 2014 | MULTI-AG | (*) $173,000,000 |
| Teva Pharmaceuticals Inc. | Teva Pharmaceutical Industries | False Claims Act and related | 2010 | MULTI-AG | $169,000,000 |
| Forest Pharmaceuticals Inc. | AbbVie | off-label or unapproved promotion of medical products | 2011 | FDA | $164,000,000 |
| SB Pharmco Puerto Rico Inc. | GlaxoSmithKline | drug or medical equipment safety violation | 2010 | MULTI-AG | (*) $163,560,000 |
| Purdue Frederick Company Inc. | Purdue Pharma | False Claims Act and related | 2007 | MULTI-AG | (*) $160,000,000 |
| Johnson & Johnson | Johnson & Johnson | off-label or unapproved promotion of medical products | 2012 | TX-AG | $158,000,000 |
| Par Pharmaceuticals, Inc. | Endo International | False Claims Act and related | 2011 | MULTI-AG | $154,000,000 |
| GlaxoSmithKline | GlaxoSmithKline | False Claims Act and related | 2005 | DOJ_CIVIL | $150,000,000 |
| Bristol-Myers Squibb Company | Bristol-Myers Squibb | accounting fraud or deficiencies | 2004 | SEC | $150,000,000 |
| Forest Pharmaceuticals Inc. | AbbVie | False Claims Act and related | 2010 | USAO | $149,000,000 |
| Valeant Pharmaceuticals International, Inc. | Bausch Health | investor protection violation | 2017 | MULTI-AG | $145,000,000 |
| Hoffman-LaRoche | Roche | price-fixing or anti-competitive practices | 2000 | MULTI-AG | $142,494,000 |
| Abbott Laboratories Inc. | AbbVie | False Claims Act and related | 2010 | DOJ_CIVIL | $126,500,000 |
| Warner Chilcott PLC | AbbVie | off-label or unapproved promotion of medical products | 2015 | FDA | $125,000,000 |
| Cephalon | Teva Pharmaceutical Industries | consumer protection violation | 2016 | MULTI-AG | $125,000,000 |
| King Pharmaceuticals | Pfizer | False Claims Act and related | 2005 | DOJ_CIVIL | $124,000,000 |
| King Pharmaceuticals | Pfizer | False Claims Act and related | 2006 | MULTI-AG | (*) $124,000,000 |
| Johnson & Johnson | Johnson & Johnson | drug or medical equipment safety violation | 2019 | MULTI-AG | $120,000,000 |
| Mylan Pharmaceuticals and UDL Laboratories | Viatris | False Claims Act and related | 2009 | DOJ_CIVIL | $118,000,000 |
| Mylan Pharmaceuticals, Inc. | Viatris | False Claims Act and related | 2009 | MULTI-AG | (*) $118,000,000 |
| Johnson & Johnson | Johnson & Johnson | drug or medical equipment safety violation | 2019 | MULTI-AG | $116,860,000 |
| Cephalon Inc. | Teva Pharmaceutical Industries | off-label or unapproved promotion of medical products | 2008 | MULTI-AG | (*) $116,000,000 |
| Avanir Pharmaceuticals | Otsuka Pharmaceutical | False Claims Act and related | 2019 | DOJ_CIVIL | $115,874,895 |
| Novartis AG | Novartis | Foreign Corrupt Practices Act | 2020 | SEC | $112,800,000 |
| AstraZeneca | AstraZeneca | False Claims Act and related | 2018 | TX-AG | $110,000,000 |
| Sanofi-Aventis U.S. Inc. | Sanofi | False Claims Act and related | 2012 | DOJ_CIVIL | $109,000,000 |
| Mylan Laboratories et al. | Viatris | price-fixing or anti-competitive practices | 2000 | MULTI-AG | (*) $108,000,000 |
| GlaxoSmithKline, LLC | GlaxoSmithKline | kickbacks and bribery | 2014 | MULTI-AG | $105,000,000 |
| Novartis Pharmaceuticals Corp. | Novartis | kickbacks and bribery | 2020 | MULTI-AG | $103,000,000 |
| Mylan Laboratories, Inc. | Viatris | consumer protection violation | 2000 | FTC | $100,000,000 |
| Mallinckrodt ARD Inc | Mallinckrodt | price-fixing or anti-competitive practices | 2017 | FTC | $100,000,000 |
| Astellas Pharma US Inc. | Astellas Pharma | False Claims Act and related | 2019 | DOJ_CIVIL | $100,000,000 |